title: The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment.
abstract: OBJECTIVE
  Reducing intraocular pressure (IOP) seems to be the only treatment that slows progression in glaucoma. The IOP can be decreased by pharmaceutical treatment, laser [selective laser trabeculoplasty (SLT)] treatment, or surgery. Prostaglandin analogues have been postulated to share action mechanisms with SLT and to possibly diminish the effects of SLT treatment. The aim of the current study was to investigate the effects of prostaglandin analogues in inflammation and IOP reduction after SLT treatment.
  
  
  METHODS
  Prospective nonrandomized study. One hundred and eighteen patients were included in the study.
  
  
  METHODS
  Glaucoma (open-angle or pseudoexfoliation glaucoma) patients who will be treated with SLT. Inflammation was measured with a laser flare meter (Kowa FM-500). Measurements were made before SLT and then 2 h, 1 week, and 1 month after SLT treatment. IOP was also checked at the same time intervals. The SLT treatment was performed over 90°. All patients were divided into two groups: those receiving prostaglandins analogues and those treated with nonprostaglandin analogues.
  
  
  RESULTS
  Inflammation before and after SLT showed no significant difference between the groups at all the time intervals studied (t-test, before: P=0.16; 2 h: P=0.14; 1 week: P=0.12; and 1 month: P=0.36). IOP reduction showed no significant difference between the groups (t-test, P=0.31).
  
  
  CONCLUSIONS
  SLT treatment effects do not seem to be influenced by the use of prostaglandin analogues.
authors.affiliation: Department of Glaucoma, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden. marcelo.ayala@sankterik.se
authors.forename: Marcelo
authors.initials: M
authors.lastname: Ayala
authors.forename: Enping
authors.initials: E
authors.lastname: Chen
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005901:Glaucoma / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D007429:Intraocular Pressure / Q000187:drug effects; D053685:Laser Therapy / Q000009:adverse effects* / Q000379:methods; D008297:Male; D011446:Prospective Studies; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D014130:Trabeculectomy / Q000009:adverse effects* / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011465:Prostaglandins, Synthetic
references.citation: Ophthalmology. 1995 Apr;102(4):613-21
references.pmid: 7724179
references.citation: Acta Ophthalmol Scand. 2007 Dec;85(8):832-7
references.pmid: 17986292
references.citation: Ophthalmology. 1996 Jan;103(1):138-47
references.pmid: 8628544
references.citation: Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2878-84
references.pmid: 1526738
references.citation: J Glaucoma. 2005 Oct;14(5):400-8
references.pmid: 16148590
references.citation: Eye (Lond). 2009 Dec;23(12):2194-9
references.pmid: 19182767
references.citation: J Ocul Pharmacol Ther. 2007 Oct;23(5):503-12
references.pmid: 17941809
references.citation: Trans Am Ophthalmol Soc. 2009 Dec;107:167-81
references.pmid: 20126493
references.citation: J Glaucoma. 2004 Feb;13(1):62-5
references.pmid: 14704546
references.citation: Arch Ophthalmol. 2003 Jul;121(7):957-60
references.pmid: 12860797
references.citation: Surv Ophthalmol. 2002 Aug;47 Suppl 1:S203-18
references.pmid: 12204717
references.citation: Ophthalmology. 1990 Nov;97(11):1403-13
references.pmid: 2255512
references.citation: Ophthalmology. 1998 Nov;105(11):2082-8; discussion 2089-90
references.pmid: 9818610
references.citation: Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1037-43
references.pmid: 14605906
references.citation: Eye (Lond). 2004 May;18(5):498-502
references.pmid: 15131681
references.citation: Am J Ophthalmol. 1995 Dec;120(6):718-31
references.pmid: 8540545
references.citation: Exp Eye Res. 1989 Sep;49(3):389-402
references.pmid: 2792235
references.citation: Ophthalmology. 1995 Dec;102(12):1743-52
references.pmid: 9098273
references.citation: J Glaucoma. 2008 Sep;17(6):497-502
references.pmid: 18794688
references.citation: Am J Ophthalmol. 2008 Jan;145(1):114-9
references.pmid: 17988642
references.citation: Arch Ophthalmol. 2004 Feb;122(2):185-9
references.pmid: 14769594
references.citation: Am J Pathol. 2001 Jul;159(1):345-57
references.pmid: 11438482
references.citation: Ophthalmology. 1997 Jan;104(1):64-71; discussion 71-2
references.pmid: 9022106
references.citation: Ophthalmology. 2008 May;115(5):790-795.e4
references.pmid: 18452763
references.citation: J Cataract Refract Surg. 2003 Jun;29(6):1055-6
references.pmid: 12842659